Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression

Abstract

Simplifying twice-daily or more frequent ARV therapy to a once-daily efavirenz-containing regimen in virologically suppressed HIV-1-infected patients maintains virologic suppression while improving adherence and patient satisfaction.